Organ system for circulating blood in animals
POPULARITY
Categories
Most people know sauna is good for them. Far fewer understand why, or why the difference between a generic infrared sauna and a precision-engineered one can be the difference between feeling good and genuine transformation. In this episode of Why Isn't Everyone Doing This?, Emily Fletcher sits down with Connie Zach, co-founder of Sunlighten, for a science-grounded, story-rich conversation about the healing power of heat and light. Connie traces the origin of her 25-year mission to her brother's recovery from mercury poisoning, and the cardiovascular research she was quietly encountering while working in pharmaceutical development at Procter & Gamble. What she found convinced her that infrared sauna was one of the most underutilized healing technologies on the planet. Together, Emily and Connie break down the four wavelengths of the infrared spectrum, why each interacts with the body differently, and why Sunlighten's patented approach to separating and delivering those wavelengths produces results that general infrared products don't. They also share the transformation stories that have fueled Connie's work for decades: Leanne Rimes managing severe anxiety with what she calls her "happiness in a box," a woman named Jerry who went from being unable to climb stairs to moving freely again, and elderly patients who dramatically increased their exercise capacity through passive infrared therapy. Emily shares why infrared sauna is one of only two wellness practices she would take with her to a desert island, and what it feels like to combine daily meditation with consistent sauna use for nervous system support. In this episode, they explore: – The four wavelengths of the infrared spectrum and how each one interacts with the body – Why far infrared is the foundation of all infrared therapy and how it triggers cardiovascular conditioning – Near infrared's deep penetration capacity, and why Dr. Glenn Jeffrey at University College London says it does 90% of the heavy lifting in light therapy – Japan's Waon therapy: a first-line treatment for congestive heart failure showing a 50% reduction in hospitalization and death – How infrared sauna mimics passive exercise by increasing circulation, heart rate, and blood flow – The link between stagnant circulation and disease, and why consistent heat therapy keeps the system flowing – Connie's brother's recovery from heavy metal toxicity and the pharmaceutical research that changed everything – Why all infrared is not the same, and what to look for in a sauna if transformation is the goal – Leanne Rimes, chronic anxiety, and "happiness in a box" – What changes on the planet when more people have access to this level of recovery Key Moments: 00:00 – Why isn't everyone understanding the magic of heat and light? 05:09 – Introducing Connie Zach and Sunlighten 06:51 – The infrared spectrum: four wavelengths, four different effects 10:40 – Near infrared vs. red light: what actually penetrates the deepest 16:05 – Connie's origin story: her brother's healing from mercury poisoning 18:27 – Cardiovascular research that changed Connie's path out of pharma 20:23 – Infrared as passive cardiovascular conditioning 21:41 – Waon therapy in Japan and the 50% hospitalization reduction 24:15 – The elderly exercise capacity study 27:36 – Emily on circulation, stagnation, and disease 35:00 – Deathbed slideshow: the transformation stories 37:22 – Leanne Rimes: "happiness in a box" 41:10 – Dr. Jeff Spencer and the Sunlighten Solo 44:57 – What changes when a billion people use heat and light About Connie Zach Connie Zach is the co-founder of Sunlighten, a precision infrared sauna company with over 25 years of research-backed innovation. Her patented SoloCarbon technology is the only clinically studied full-spectrum infrared available. This episode is sponsored by Sunlighten. Save up to $2,100 + free shipping at get.sunlighten.com/zivapodcast
In this episode, we review the high-yield topic of Cardiac Tamponade from the Cardiovascular section at Medbullets.comFollow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets
Las enfermedades cardiovasculares continúan siendo una de las principales causas de atención médica en la población adulta.En algunos casos, el tratamiento requiere procedimientos quirúrgicos para corregir alteraciones del corazón o de los vasos sanguíneos y mejorar la calidad de vida.En este programa hablaremos sobre cuándo se considera una cirugía cardiovascular, cuáles son los procedimientos más frecuentes y qué aspectos influyen en la recuperación y el seguimiento posterior.
Your eyes reveal what you cannot see. Advanced OCT and OCT Angiography technology now allows eye care professionals to detect and prevent diseases that would otherwise lead to blindness and to diagnose systemic conditions like diabetes, hypertension, and cardiovascular disease before symptoms appear. In this episode, Dr. Kerry Gelb sits down with Dr. Carolyn Majcher, a leading expert in retinal imaging and vitreoretinal disease, to explore how this breakthrough technology is transforming preventive medicine. ❤️ WHY THIS MATTERS: Early detection saves vision. Early detection saves lives. Eye imaging now detects: ✓ Diabetes (before the patient knows) ✓ Hypertension (silently damaging organs) ✓ Cardiovascular disease (showing warning signs in the retina) ✓ Retinal diseases (before blindness occurs) ✓ Systemic conditions (through the eye as a biomarker) Connect with Dr. Carolyn Majcher: https://www.instagram.com/retina_queen/
Fontes do episódio aqui:https://portal.afya.com.br/podcasts/afya-news/19-06-2026Nesta sexta-feira, o boletim destaca dados históricos de sobrevivência oncológica, um mapeamento populacional massivo sobre demência e campanhas vacinais emergenciais na Europa. Analisamos o estudo da Queen Mary University of London que comprovou que a vacinação contra o HPV em adolescentes reduz a quase zero o risco de morte por cancro do colo do útero antes dos 30 anos. Detalhamos a análise epidemiológica com 800 mil pacientes que conectou a hipotensão, a hipertensão e o AVC a um risco significativamente maior de Doença de Alzheimer. Por fim, abordamos no Radar o surto letal de Meningite B no Reino Unido, que impulsionou uma vacinação emergencial focada em jovens universitários. Afya News. Informação médica confiável e atualizada no seu tempo.
This week we talk about LDL, HDL, and cardiovascular issues.We also discuss one-time therapies, statins, and pharmaceutical economics.Recommended Book: Blood by Dr. Jen GunterTranscriptCholesterol is the most common type of what's called a sterol, which is a type of steroid, but also structurally technically an alcohol. But functionally, and classified by scientists, cholesterol is a lipid, which in this case is similar to a fat in all but how the body uses it. Cholesterol is the type of sterol most commonly found in animals—other types are found in plants and fungi—and its function, and this is where it varies from fats, which are used to store energy, is to basically help hold the cell membrane together, and it also serves as an intracellular messenger.Cholesterol is especially prevalent in the brain and spinal cord of animals, but it's found throughout their bodily tissues, as well, and again, it's vital for holding everything together and helping things communicate, in addition to being a precursor for vitamin D, steroid hormones, and bile.You want to have cholesterol, then, as without it you would be dead.Too much cholesterol in the blood, however, can also make you dead, especially when it's bound to what's called low-density lipoprotein, or LDL, as that contributes to cardiovascular disease like heart attacks and aneurysms, which can massively impact one's overall wellness and quality of life, and at extremes lead to the whole system shutting down as a consequence of heart attack, stroke, and the like.A lot of things can contribute to the development of cardiovascular disease, including habits like smoking, genetic predisposition, and the enthusiastic consumption of alcohol and unhealthy foods. But high blood cholesterol, of the LDL variety, is one of the top contributors, as these low-density clusters of lipoprotein can clog the pathways that blood takes throughout our bodies. Other, denser types of lipoproteins, HDLs, can clear it, like a heavier, denser substance pushing through clogs of less-dense materials that are gumming up a pipe, but LDL is at times accumulated as a result of consuming delicious but unhealthy foods, which are hard to avoid, and for some people the only consistently available and affordable foods; and for other people LDL accumulates as a result of their genetic predispositions—two things that are devilishly difficult to change.What I'd like to talk about today is a new type of therapy that may be very good news for people who struggle with the accumulation of LDL, and why this is being seen as very good news more broadly, at the scale of entire nations, as well.—Pharmaceutical company Eli Lilly is testing a new, experimental drug called VERVE-102 which is a one-time infusion that is currently administered over the course of about four hours, and once completed, it turns off a gene called PCSK9, which is responsible for making a protein that regulates cholesterol levels in humans.As I said, this drug is still being tested, so these are early results. But in a study of 35 people with high cholesterol levels, high levels of LDL or LDL-C, which is short for lipoprotein cholesterol, they found that this infusion, which again, is a one-time treatment, so get it once and then theoretically at least you never have to get anything done ever again, it reduced those LDL and LDL-C levels by as much as 62%, and that reduction was maintained a year and a half after the infusion; that's how far out they're retested so far, and the hope is that each retest will continue to show the same.On the strength of those very promising results, a Phase 2 study has been planned by the end of 2026, and the US Food and Drug Administration, the FDA, previously fast-tracked this existing study, because of the promise and potential this drug already demonstrated in early studies; all of which is considered to be very significant progress and possibility.To understand that significance, though, it's useful to know some health stats. And I'm going to focus on the US here, as that's where this drug is being developed, but many wealthy countries have similar stats, at least in terms of cardiovascular disease struggles.As of 2024, which is the last year we had good, cohesive data on this in the US, it was estimated that about 11-12% of the US adult population has high cholesterol levels. This typically doesn't come with any symptoms, but it can contribute a higher risk for all those cardiovascular diseases, including heart attack and stroke. A further 86 million US adults have borderline or elevated cholesterol levels, which can easily tip higher, but also, even in that existing, elevated state, contribute to negative cardiovascular outcomes.There are treatments for high cholesterol, the most common of category of which are called statins, which reduce the production of LDL by inhibiting an enzyme that produces cholesterol in the body.Unfortunately, these drugs do come with some usually minor side effects, which can cause patients to stop using them, and they have to be taken daily, ideally at the same time each day. That necessity for consistency leads to a lot of incorrect or incomplete usage, which reduces the effectiveness of these drugs. But it's also estimated that only about 54.5% of US adults who would benefit from statins are currently taking one—so that's people who could benefit and who have it prescribed, and then within that number are all the people who are taking this drug incorrectly or incompletely, reducing the effectiveness. So a relatively small number of people who should probably be on these things are getting the full benefit they offer because of the nature of the drug.And that's not great, because in the US alone, heart disease is the leading cause of death for pretty much every adult demographic; men, women, people of most racial and ethnic and economic groups, you name it, heart disease is the biggest threat to their lives.One US citizen dies every 34 seconds of some kind of cardiovascular condition, and as of 2023, 1 in every 3 deaths in the US was caused by the same, adding up to just over 919,000 people that year.Between 2021 and 2022, alone, the cost of services and medications related to heart disease added up to more than $168 billion; again, that's just in that period, and just in the US.And once more, these are ailments that are caused or heavily influenced by high levels of cholesterol, which are themselves amplified by common lifestyle choices, environmental factors that are hard for many people to avoid, and just by raw, dumb luck because of genetics.This treatment category, then, is being seen as a pretty big deal because a one-time infusion means those who receive it don't have to remember to take a pill every day at the same time, and won't experience those statin-based side-effects.It also means that people who are currently costing the medical system a bunch of money each year, because they need treatments for all the issues they suffer as a result of high cholesterol, will suddenly cost the system a lot less money, for treatments and medications. Not for nothing, their health and quality of life will likely improve as well. So in addition to having better, healthier outcomes personally, their cost to healthcare systems will drop.Eli Lilly's drug isn't the only one currently working its way through clinical trials, either.Amgen is working on a similar treatment, and Novartis and Ionis Pharmaceuticals have drugs that are even further along in the process, their medicines that cut heart attacks, strokes, and cardiovascular deaths could be approved by the FDA as soon as next year.There are a lot of caveats worth noting here, including that the science is still out as to whether this approach, silencing proteins that lead to the creation of more LDL and a similar substance called Lp(a)—which is more dangerous because it's stickier and thus more likely to get stuck in important blood pathways, and it's also more likely to be caused by genetics than lifestyle—the word is still out on whether reducing these things in the body actually reduces hearth attacks and stroke.Some people have had this particular risk variable dramatically reduced, but have still suffered from cardiovascular events, which raises the question of whether this path is the right one to take in trying to reduce this category of health issues; the correlation between LDL and heart attacks and strokes might not be a clear-cut as long assumed.There's also the issue of price. Drug-makers are economically incentivized to sell treatments over cures, because that means they can continue selling their product over time, potentially for the life of the patient, and a cure, in contrast, is a one-time hit that in theory should alleviate the need for future treatment.There's a chance, then, that the drug-makers will decide they need to make these one-hit treatments really, really expensive in order to make their R&D dollars back and to make the kinds of profits their investors expect from them. That could then reduce the potential audience for these treatments, even if they are effective, and could further slow their deployment and future research in this space.If these trials continue to go well, though, there's a good chance that this combination of similar but distinct treatment types will provide a more sustainable alternative to current options, and that, like the recent bogglingly rapid and widespread deployment of GLP-1 treatments for all sorts of issues, could lead to a new paradigm in this facet of the medical world.Show Noteshttps://en.wikipedia.org/wiki/Cholesterolhttps://en.wikipedia.org/wiki/Cardiovascular_diseasehttps://en.wikipedia.org/wiki/High_cholesterolhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10982736/https://www.cdc.gov/heart-disease/data-research/facts-stats/index.htmlhttps://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1https://www.ama-assn.org/public-health/chronic-diseases/what-doctors-want-patients-know-about-high-cholesterolhttps://en.wikipedia.org/wiki/Statinhttps://pubmed.ncbi.nlm.nih.gov/42187087/https://abcnews.com/GMA/Wellness/new-drug-game-changer-people-high-cholesterol/story This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit letsknowthings.substack.com/subscribe
I am delighted to have the privilege of reconnecting with Dr. Deb Matthew today. She joined me once before on Episode 259. She is a distinguished best-selling author, international speaker, and dedicated educator known as the Happy Hormone Doctor. Cardiovascular disease is the number one killer of women in the United States, causing one of every 3.2 deaths among women annually. In our conversation today, Dr. Matthew and I delve into the realm of cardiovascular disease, exploring the benefits of hormone replacement therapy, essential laboratory testing, medications, and the neurocognitive changes that occur during perimenopause and menopause. We also focus on lifestyle, gut testing, and the all-time favorite topic: weight-loss resistance. Stay tuned for today's engaging, enriching, and enlightening discussion with Dr. Deb Matthew. IN THIS EPISODE YOU WILL LEARN: How HRT reduces the risk of cardiovascular disease How long-term use of estrogen can reduce the risk of heart disease over time Why you should do a hormone panel before starting HRT How cortisol levels impact cardiovascular health How the coronary calcium score helps to predict heart attack risk Cholesterol markers and their significance in cardiovascular risk assessment Managing cholesterol levels in perimenopausal women The importance of addressing underlying hormonal imbalances in women to mitigate cognitive decline and lipid disorders The connection between gut health and brain fog How women's testosterone levels impact their cognition and motivation Hormone imbalance and weight loss resistance in women Connect with Cynthia Thurlow Follow on X, Instagram & LinkedIn Check out Cynthia's website. Submit your questions to support@cynthiathurlow.com Join other like-minded women in a supportive, nurturing community: The Midlife Pause/Cynthia Thurlow. Purchase Cynthia's book, The Menopause Gut. Cynthia's Intermittent Fasting Transformation Book The Midlife Pause Supplement Line Connect with Dr. Deb Matthew On her website Facebook Instagram Dr. Deb Matthew's book This is Not Normal on Amazon Previous Episode featuring Dr. Matthew Ep. 295: HRT's Impact on Women's Health Through Time with Dr. Deb Matthew
Federico y el Dr. Enrique de la Morena hablan con el Dr. Borja Ibáñez, director científico del Centro Nacional de Investigaciones Cardiovasculares.
Could you have metabolic dysfunction even at a normal weight?This episode challenges everything we've been taught about weight and health. Dr. Cooper reveals that up to 25% of normal-weight people have metabolic syndrome, yet they're rarely screened because doctors assume they're healthy based on appearance alone.KEY TAKEAWAYSWeight and metabolic health are not the same thing - you can be metabolically unhealthy at any sizeNormal weight people with metabolic dysfunction are often overlooked and undertreated by healthcare providersKey screening tests include fasting glucose, insulin, HbA1c, triglycerides, HDL cholesterol, blood pressure, and inflammatory markers like HSCRPMetabolic dysfunction can start in your 20s and take decades to develop into serious diseaseBoth normal weight and higher weight patients face bias - normal weight people aren't screened enough, while higher weight people have everything blamed on their weightEarly screening and treatment can prevent catastrophic health outcomes later in lifeThe liver plays a crucial role in metabolism and can become insulin resistant regardless of body weightNOTABLE QUOTE"You cannot tell anything about someone's health from their outside, what they look like or what, even what they're doing necessarily, but definitely not their body size. So you can be healthy or unhealthy at any size body, and I think that's what's overlooked quite a bit." — Dr. Emily CooperLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comAppendix: Key ReferencesPrimary literature supporting this episode• Wang et al. Prevalence of Metabolically Unhealthy Normal Weight and Its Influence on the Risk of Diabetes. Journal of Clinical Endocrinology & Metabolism, 2023.• Review: Beyond BMI — Rethinking Obesity Metrics and Cardiovascular Risk in the Era of Precision Medicine. Journal of Clinical Medicine, December 2025.• Korean meta-analyses on metabolic dysfunction phenotypes and cardiometabolic risk, Cardiovascular and Metabolic Sciences Journal review, 2024.• Frontiers in Nutrition, January 2026. Associations of metabolic heterogeneity with the progression of cardiometabolic multimorbidity.• International Journal of Obesity, September 2025. Cardiovascular risk factors associated with metabolic health phenotypes.Mechanism references• MASLD — metabolic dysfunction-associated steatotic liver disease — nomenclature and clinical framework. AASLD/EASL consensus, 2023.• Insulin signaling, adipose tissue dysfunction, and ectopic fat deposition — reviews on the upstream-downstream relationship.• Epicardial adipose tissue and cardiovascular dysfunction — Frontiers in Cardiovascular Medicine, January 2026.Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.
With Benjamin Peter Geisler, University of Oslo, Oslo - Norway and Arnab Gosh, Weill Cornell Medical College, New York - USA. Link to European Heart Journal paper Link to European Heart Journal editorial
This episode explores how translational research bridges the gap between scientific discovery and real-world patient care, and highlights the nurse's pivotal role in clinical trials. Tune in to guests Brittany Butts, PhD, RN, and Erin Ferranti, PhD, MPH, RN, FAHA, FPCNA, FAAN, to learn how you can champion research, from participation to publication, and drive meaningful change in healthcare.Link to the Cardiovascular Nursing Certificate here: https://pcna.net/career-development/cardiovascular-nursing-certificate/See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
This episode equips nurses with practical tools to assess and manage patients with cardiometabolic risks like obesity, hypertension, and diabetes. Guests Yvonne Commodore-Mensah, PhD, MHS, RN, and Cindy Lamendola, MSN, NP, dive into the power of lifestyle changes to reduce these risks, while also breaking down the latest clinical guidelines and pharmacotherapies to keep your practice current and effective. Link to the Cardiovascular Nursing Certificate: https://pcna.net/career-development/cardiovascular-nursing-certificate/See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
In this episode, we review the high-yield topic of Orthostatic Hypotension from the Cardiovascular section at Medbullets.comFollow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets
One American dies from heart disease every 33 seconds — and yet, with all of our technology, all of our specialists, and all of our medications, we are still losing this fight. On today's Health Talk America, Dr. Adam Brockman exposes the fatal flaw in conventional cardiology: we've been treating numbers on a lab report instead of the underlying biology producing those numbers. The real story begins decades before your first symptom — in a one-cell-thick lining inside your arteries called the endothelium. Nobel Prize- winning science has identified the critical molecule your cardiovascular system depends on, and the overwhelming majority of Americans over 40 are running dangerously low on it right now. Dr. Nathan Bryan joins the program to reveal what time and lifestyle have taken from your heart — and exactly how to get it back.Special Guest: Dr. Nathan Bryan, Nitric Oxide Expert of N1O1.com
In this episode, we review the high-yield topic of Mitral Regurgitation from the Cardiovascular section at Medbullets.comFollow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets
This week we go back 2.5 years and delve into the world of cardiovascular surgery when we review a review of STS data on the pulmonary artery band (PAB). The STS assigns a STAT category of 4 to this operation, denoting higher risk for mortality. Is this warranted? Are all PAB candidates equal? What features are associated with higher or lower mortality rates in patients undergoing banding? Should the data in this work drive innovation to avoid the PAB in some settings? These are amongst the questions posed to the senior author of this week's work, cardiovascular surgeon Dr. Tara Karamlou who is Professor of Surgery at the Cleveland Clinic in Cleveland, Ohio. DOI: 10.1016/j.athoracsur.2023.09.020
In this episode, we review the high-yield topic of Blunt Cardiac Injury from the Cardiovascular section at Medbullets.comFollow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets
Drs. Benjamin Catanese and Daniel Edmonston discuss their study, "Cardiovascular Outcomes among New Users of GLP-1 Receptor Agonists Compared with DPP-4 Inhibitors and Sulfonylureas in Kidney Failure," with JASN Deputy Editor Manjula Kurella Tamura.
In this episode, we review the high-yield topic of Antianginal Drugs from the Cardiovascular section at Medbullets.comFollow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets
The new 2026 AHA/ACC/ADA/ASN Cardiovascular–Kidney–Metabolic (CKM) Guideline reframes chronic disease through a unified lens connecting obesity, diabetes, chronic kidney disease, and cardiovascular disease. Key themes: ✅ CKM staging across the life course ✅ PREVENT risk assessment for personalized care ✅ Early detection of kidney and cardiometabolic risk ✅ Lifestyle and weight management as foundational therapy ✅ Evidence-based use of SGLT2 inhibitors and GLP-1–based therapies ✅ Team-based, patient-centered care A landmark step toward integrated prevention and better long-term outcomes. #Cardiology #Nephrology #Diabetes #Obesity #CKM #PreventiveCardiology #MedicalPodcasts #PrecisionMedicine #HeartFailure #KidneyDisease
Cardiovascular disease is often thought of as a heart problem, but its effects reach far beyond the cardiovascular system. In this episode, Dr. Gavin Guard explores the root causes of cardiovascular disease through a functional medicine lens, breaking down how chronic inflammation, metabolic dysfunction, nutrition, and lifestyle choices influence long-term heart health. You'll learn how cardiovascular disease develops, the warning signs to watch for, and the connection between factors like high blood pressure, cholesterol imbalances, insulin resistance, and overall wellness. Dr. Holthouse also discusses evidence-based strategies for reducing risk and improving healthspan through personalized care and preventive medicine. Whether you're looking to better understand your cardiovascular risk, support a loved one, or take proactive steps toward a healthier future, this episode provides practical insights and actionable takeaways grounded in current science. In this episode, you'll learn: What cardiovascular disease is and why it's so common How inflammation contributes to heart disease The relationship between cholesterol, blood pressure, and cardiovascular risk Why metabolic health plays a major role in heart health Functional medicine approaches to prevention and treatment Lifestyle strategies that support a healthy cardiovascular system Steps you can take today to reduce your risk of heart attack and stroke Stay tuned in for more conversations on functional medicine, preventive healthcare, longevity, and optimizing your health from the inside out!
MedAxiom HeartTalk: Transforming Cardiovascular Care Together
In this MedAxiom HeartTalk, host Melanie Lawson, MS, sits down with Maureen Knechtel, DMSc, PA-C, academic coordinator and associate professor of physician assistant studies at Milligan University, and Jerry Blackwell, MD, MBA, FACC, president and CEO of MedAxiom. They challenge the idea that onboarding begins and ends with orientation, revealing a gap many organizations don't recognize until it's too late. Their conversation explores what it takes to develop APPs with intention and set them up for long-term success.
Justin Coleman chats with nephrologist Karen Dwyer about her paper on cardiovascular-kidney-metabolic (CKM) syndrome. Karen outlines the underlying conditions, pathophysiology, and stages of progression associated with CKM syndrome. The conversation also covers the importance of managing CKM syndrome with both behavioural and lifestyle modifications as well as medications. Read the full article in Australian Prescriber.
Send us Fan MailLearning objectives: 1- Identify main objective of the TRAVERSE study and be familiar with its outcomes pertaining to the primary safety end point of MACE2- Identify other possible Adverse events associated with testosterone replacement therapy and contrast them with other systematic reviews and meta analyses already published Support the show
Welcome back to the communal Schauer, make sure to don your tin foil hat because this week we're wading into the murky waters of interventionism and bungled progress. A word of warning to those of childbearing age: I swear a lot in this and it has been scientifically proven that profanity makes your ovaries grieve. Tear. Pour. Live More. Go to https://LiquidIV.com and get 20% off your first purchase with code SCHAUER at checkout Download Hily Dating App from the App Store or Google Play, or visit https://hily.go.link/jRMKW And yes, I do apologize for the late upload, I'm trying to get the hang of recording at home. I appreciate everyone's patience, you all are incredible and should be celebrated. I hope you all enjoy this week's episode! The Allen Institute's Collab w/ KEXP https://alleninstitute.org/kexp I helped with this! General Resources: Alzheimer's Disease https://emedicine.medscape.com/article/1134817-overview#a2 Anatomy, Abdomen and Pelvis: Celiac Ganglia https://www.ncbi.nlm.nih.gov/books/NBK538129/#article-19097.s6 Federal Food, Drug, and Cosmetic Act of 1938 https://www.ncbi.nlm.nih.gov/books/NBK585046/ Toxic Effects of Mercury on the Cardiovascular and Central Nervous System https://pmc.ncbi.nlm.nih.gov/articles/PMC3395437/ Tampons as a source of exposure to metal(loid)s https://www.sciencedirect.com/science/article/pii/S0160412024004355 Patents on Psychedelics: The Next Legal Battlefront of Drug Development https://harvardlawreview.org/forum/no-volume/patents-on-psychedelics-the-next-legal-battlefront-of-drug-development/ Caffeine-Induced Psychosis: A Case Report and Review of Literature https://pmc.ncbi.nlm.nih.gov/articles/PMC11376648/ The effect of caffeine and stress on auditory hallucinations in a non-clinical sample https://www.sciencedirect.com/science/article/abs/pii/S019188691000591X Scientists Stop Pancreatic Cancer Before It Starts in Landmark Preclinical Study https://scitechdaily.com/scientists-stop-pancreatic-cancer-before-it-starts-in-landmark-preclinical-study/ The Brain Waste System Disrupted by Alzheimer's Mapped https://neurosciencenews.com/glymphatic-brain-waste-clearance-30785/ The Resurgence of Hallucinogen Drugs in Clinical Research https://www.sciencedirect.com/science/article/pii/S0034837625001457 Residential psychedelic (LSD) therapy for the narcotic addict. A controlled study https://pubmed.ncbi.nlm.nih.gov/4575166/ This study is from 1973 - if you would do me the favor of scrolling down to the “similar articles” section I'd like you to note the dates of publication for related research. If you're seeing what I'm seeing, psychedelics could've really helped a lot of people. Books Clean: The New Science of Skin and the Beauty of Doing Less - James Hamblin Natural Capitalism: Creating the Next Industrial Revolution - Paul Hawken Undermining Science: Suppression and Distortion in the Bush Administration - Seth Shulman Sweet and Deadly: How Coca-Cola Spreads Disinformation and Makes Us Sick - Murray Carpenter How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence - Michael Pollan Unwell Women: Misdiagnosis and Myth in a Man-Made World - Elinor Cleghorn A History of Transgender Medicine in the United States: From Margins to Mainstream - Carolyn Wolf-Gould, Dallas Denny, Jamison Green, Kyan Lynch, Editors Food & Lobbying Resources: Nutrition Websites & Databases https://libguides.regiscollege.edu/nutrition/intro EWG's Food Scores https://www.ewg.org/foodscores/ Open Secrets https://www.opensecrets.org/ Learn more about your ad choices. Visit podcastchoices.com/adchoices
In this episode, Peter George, MD, MBA, FACC, FASE, FASNC, Chief Medical Officer of Cardiovascular Services at UnityPoint Health, joins the podcast to discuss optimizing medical therapy and expanding outpatient care strategies to keep patients healthier and out of the hospital. He also shares approaches to lowering readmission rates and improving long-term cardiovascular outcomes through coordinated, proactive care.
Welcome back! Today, we are looking at Modafinil and it's nuanced use in psychiatry.References:Provigil (modafinil) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc. U.S. Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfdadocs/label/2015/020717s037s038lbl.pdfSchwartz JR. Modafinil in the treatment of excessive sleepiness. Drug Des Devel Ther. 2009;2:71–85.Kaplan S, Goehring EL Jr, Engel T, et al. Cardiovascular outcomes associated with modafinil in patients with obstructive sleep apnea. Pharmacoepidemiol Drug Saf. 2018;27(11):1182–1190. doi:10.1002/pds.4642Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727–738. doi:10.1016/S2215-0366(18)30269-4Goss AJ, Kaser M, Costafreda SG, Sahakian BJ, Fu CH. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry. 2013;74(11):1101–1107. doi:10.4088/JCP.13r08560Bahji A, Mesbah-Oskui L. Comparative efficacy and safety of stimulant-type medications for depression: a systematic review and network meta-analysis. J Affect Disord. 2021;292:416–423. doi:10.1016/j.jad.2021.05.119Nunez NA, Singh B, Jorgensen A, et al. Efficacy and tolerability of adjunctive modafinil/armodafinil in bipolar depression: a meta-analysis of randomized controlled trials. Bipolar Disord. 2020;22(2):109–120. doi:10.1111/bdi.12859
Guest James Norton, BSN, RN, FPCNA, describes the use of AI in nursing practice, focusing on Large Language Models (LLMs). James shares how to effectively craft a prompt to get the results you need whether you are looking for information on clinical references or guidelines, or drafting appeal letters for denied prior authorizations, and the importance of reviewing AI outputs with a critical eye. Related PCNA Resources: Article: Artificial Intelligence: Opportunity for Positive Transformations in Cardiovascular Disease ManagementCE Course: The Role of Artificial Intelligence in Cardiovascular Care: ATTR Case StudyCE Course: Artificial Intelligence: Leveraging AI for CVD ManagementSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
This week we review a recent report from the team at Amrita Institute in Cocchin, India about their use of extended reality and virtual reality as well as heart model printing to aid in planning for complex intracardiac baffles for the treatment of complex congenital heart defects. What was the process used to provide actionable advice in the operating room during surgery? How has the team in southern India created a workflow that can accurately predict this complex anatomy and the patches needed to successfully septate complex hearts? We speak with the director of the 3D imaging group at Amrita, Professor Mahesh Kappanayil about this remarkable achievement of imaging in collaboration with surgery. DOI: 10.1016/j.jtcvs.2026.03.616
Show Notes Pediatric vital signs are more than numbers on a monitor — they are part of a larger clinical picture that includes development, physiology, behavior, medical complexity and careful observation. In this episode of Acute Conversations, host Dr. Leo Arguelles is joined by Ashley Parish, PT, DPT, PhD, CRT, CCS, and Dawn Drumm, PT, DHSc, two contributors to the new Pediatric Vital Signs Guide. Together, they discuss how the resource came to life, why collaboration across APTA Acute Care, the Academy of Cardiovascular and Pulmonary Physical Therapy, and pediatric clinicians was essential, and how the guide can support therapists across settings. Ashley and Dawn share the challenges of building a practical document from variable pediatric references, the importance of using the guide alongside clinical reasoning, and why pediatric knowledge matters even for therapists who primarily treat adults. From infants in the NICU to adults living with congenital conditions, this episode highlights the need to think across the lifespan. Today's Guests: Dawn Drumm PT, DHSc ddrumm@luriechildrens.org https://www.linkedin.com/in/dawn-drumm-b141b455/ IG: drummdawn Ashley Parish PT, DPT, PhD, CRT, CCS ashbrown@uab.edu https://www.linkedin.com/in/ashley-parish-pt-dpt-phd-crt-ccs-b98b60273/ IG: ashleyparish_pt Guest Quotes: 18:31 Ashley “ What we came up with originally, and Dawn will probably laugh, it’s a massive- massive document. It was a textbook. And we were like- … “Yeah, we gotta shave this down and make it like a guide people can actually use in clinic practice.” 21:05 Dawn “First look at the document, it’s a great overview of just the lifespan within a pediatric lens. And so honing in on those first few areas of content, it just gives you kind of basics. Heart rate through the lifespan, your, respiratory rate… I think that beginning section is really important to highlight so that way you’re getting your foundational guidance that way.” 28:51 Ashley “ If you specifically wanna go into acute care peds, sometimes it’s difficult to find a job because there aren’t as many pediatric hospitals as there are adult hospitals, so just hang in there if it’s really hard for you to get on at first. Get experience in acute care. That always looks really good if you go from an adult hospital to a pediatric hospital. But those jobs do open up, so just be patient if you can’t find one right out of school ’cause no one likes to leave pediatric acute care. It’s the best setting.” Rapid Responses: What's your favorite color scrubs to wear while you’re at work? Ashley “ Oh, since I’m a peds therapist, it’s always fun, bright colors. I would say Barney purple is my favorite set. Barney purple.” Dawn “ Okay. So sadly, we don’t actually have to wear scrubs at work. Oh, wow … and we don’t have a color. But I feel like physical therapy was always blue. We always were like- … blue at county, Going with my basic blue.” You know you’re an acute care therapist when… Ashley “You have a distain for purewicks.” Dawn “ You've have changed more diapers than you would probably like. Yes. So getting down- In both adult and pediatrics, right? Both. Oh, yes … you can’t get away without poop talk.” Links: Pediatric Vital Sign Interpretation in Acute Care Guide 2025 https://www.mdpi.com/2077-0383/13/24/7681/xml https://www.sralab.org/research/labs/max-nader-rto/projects/intervention-promote-motor-development-infants
Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Accelerometer-Measured Sedentary Behavior, Future Disease, and Cardiovascular-Kidney-Metabolic Health.
In the first episode of this series on Obesity, our host is joined by Dr. Mikhail Kosiborod to discuss the evolving science and cardiometabolic diseases associated with obesity. This special episode is sponsored with support from AstraZeneca. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Mikhail Kosiborod, MD, Senior Vice President Late-Stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D at AstraZeneca. Selected references: Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation October 2023
Direct-to-consumer healthcare is changing how patients engage with care, driven by growing demand for convenience, accessibility, and personalized experiences. VerifiedRx host Stacy Lauderdale is joined by Emily Fitt, Hailey Mulliner, and Heather Pace to discuss the continued rise of telehealth and direct-to-consumer healthcare platforms, the areas experiencing the most growth, and what these evolving models may mean for patients, providers, and health systems in the future. Guest Speakers: Emily Fitt, MHA, MPH Senior Associate, Sg2 Intelligence Vizient, Inc. Hailey Mulliner, MS-HSM Senior Director, Sg2 Intelligence Vizient, Inc. Heather Pace, Pharm.D. Senior Clinical Manager, Ambulatory Vizient, Inc. Host: Stacy Lauderdale, Pharm.D., BCPS AVP, Evidence-Based Medicine Vizient Show Notes: (00:52) The panel discusses where direct-to-consumer healthcare has gained the most traction, including: Men's reproductive health Women's contraceptives Dermatology and acne care Behavioral health GLP-1 and obesity management (01:59) Heather explains how GLP-1 medication shortages fueled growth in compounded obesity medications and expanded telehealth services. (02:47) Hailey shares insights from SG2 consumer surveys, emphasizing how patients increasingly want customizable, convenient healthcare experiences like other consumer industries. (03:26) The group explores future expansion areas for direct-to-consumer healthcare, including: Cardiovascular disease management Type 2 diabetes Orthopedic care Cardiometabolic disease monitoring (04:31) Discussion shifts to the benefits and drawbacks for patients, including: Increased convenience and access More comfortable treatment environments Greater patient empowerment Risks of fragmented care and disconnected treatment plans (06:07) Emily outlines concerns for health systems, including: Increased emergency department utilization Lack of coordinated care Medication management gaps Challenges identifying medications prescribed outside the health system (07:03) Heather discusses medication stewardship concerns, particularly as weight loss impacts management of other chronic conditions like hypertension. (07:29) The panel highlights operational challenges for hospitals and procedural teams when patients fail to disclose GLP-1 medications prior to surgeries or colonoscopies. (07:58) The conversation turns to how direct-to-consumer healthcare is permanently changing consumer expectations around convenience and accessibility. (08:36) The panel debates whether health systems should compete with direct-to-consumer companies or pursue partnership strategies. (09:51) Emily discusses how health systems can differentiate themselves by offering the full continuum of care that virtual only providers cannot. (10:20) Heather Pace emphasizes the importance of partnerships between health systems and direct-to-consumer platforms to improve access while maintaining coordinated care. (10:55) The group discusses emerging partnerships in the marketplace, including collaborations between pharmaceutical manufacturers and direct-to-consumer platforms. (12:14)Workforce challenges are explored, including: Competition for clinicians Provider burnout Flexibility offered by virtual care employers (13:17) The panel examines future trends involving AI, including patients using AI to interpret labs and emerging AI-assisted prescribing models in behavioral health. (14:24) Closing thoughts on how direct-to-consumer healthcare is reshaping patient expectations and forcing health systems to rethink care delivery models. Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed
Focus Issue on Cardiovascular risk prediction beyond accepted scores
In this episode, Ian Cohen, MD, Charles and Barbara Strang Medical Director of the Bluhm Cardiovascular Institute, Northwestern Medicine Catherine Gratz Griffin Lake Forest Hospital, and Sarah Plaskett, MBA, MMS, PA, Vice President of Operations at the Northwestern Medicine Bluhm Cardiovascular Institute, discuss how they are building advanced cardiovascular programs in community settings through intentional growth, integrated leadership, and a strong focus on quality outcomes.
Is progesterone the same as a progestin? It sounds like it should be. It is absolutely not. And that distinction matters more than most women — and many providers — realize.This is the conversation Dr. Carolyn Moyers has multiple times a day in clinic — especially with women in perimenopause who are trying to understand their options, figure out why a previous hormone regimen made them feel worse, or advocate for a prescription that actually fits their biology. It is also one of the most consequential mix-ups in all of menopause medicine, and it is long overdue for a dedicated episode.Bioidentical progesterone and synthetic progestins are not interchangeable. They have different molecular structures, different receptor profiles, and meaningfully different effects on your breast tissue, your cardiovascular system, your sleep, and your brain. The WHI study — the one that scared a generation of women off hormone therapy — tested a synthetic progestin, not bioidentical progesterone. And the breast cancer finding it reported was not even statistically significant. That context has been almost entirely missing from the public conversation. Until now.In this episode:• What bioidentical progesterone actually is — and how it differs from synthetic progestins at the molecular level• The WHI study: what it actually tested, and why its results have been misapplied for 20+ years• Breast cancer risk: the ESTHER study and what the evidence actually shows• Cardiovascular differences between progesterone and MPA (Provera)• Why progesterone is a neuroactive steroid — and what that means for your sleep, anxiety, and mood• Uterine protection: what it is, why it matters, and whether bioidentical progesterone is sufficient• What to do if you don't have a uterus — and whether you still need progesterone• Perimenopause: why the progestogen conversation is completely different when you still have cycles, variable ovarian function, and potentially need contraception• The levonorgestrel IUD, norethindrone acetate 5mg vs. the minipill, and Slynd (drospirenone 4mg) — what each one does and who it's for• Exactly how to advocate for yourself at your next appointmentResources mentioned:• ESTHER Study (Fournier et al.) — progesterone vs. MPA and breast cancer risk• Women's Health Initiative (2002)• Prometrium prescribing information• Labia Logic (@labialogic) — vulvovaginal specialists | Memorial Day vulvar health post: instagram.com/p/DYqK9uvj2M8• Sky Women's Health Podcast — Episode 158: Progesterone Intolerance | podcasts.apple.com/gb/podcast/episode-158-progesterone-intolerance/id1541657642?i=1000640152675Work with Dr. Moyers: skywomenshealth.com | In-person: Fort Worth, TX | Virtual: Texas & West Virginia
Leave an Amazon Rating or Review for my New York Times Bestselling book, Make Money Easy! Check out the full episode: https://greatness.lnk.to/1815DM Your child's brain is already losing connections. Not because something's wrong. Because of pruning. The brain cuts whatever isn't being used. Dr. Baland Jalal says the window is real, and what you do in it matters. Affection first. Hugging and physical touch trigger oxytocin and neuropeptides that directly support neuroplasticity. It's not soft parenting. It's brain science. Then real stimulation. Not screens. Screens wire dopamine addiction loops. The stimulation that builds the brain is social. Learning to read faces, pick up on emotional cues, engage with other humans. Dr. Jalal admits COVID isolation left him socially handicapped. His mirror neurons went quiet. And finally: let them run. Cardiovascular exercise produces BDNF, what he calls "fertilizer for the brain," which grows new synapses. The last one is easy to miss: convey passion. Kids catch it from the adults around them. Sign up for the Greatness newsletter: http://www.greatness.com/newsletter Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
This week we review a landmark paper from the NEJM by the SCOUT-HCM study group assessing the impact of mavacamten on HCM in the adolescent patient. How does this agent work and what impact did it have on the LVOT gradients in obstructed HCM teens? Does this agent affect other biomarkers associated with more obstruction in this setting? Who is a good potential candidate for the use of this agent? Why must the EF be carefully monitored while using this agent? Dr. Joseph Rossano, Professor of Pediatrics at The University of Pennsylvania and the chief of pediatric cardiology at The Children's Hospital of Philadelphia joins the podcast to discuss this groundbreaking work.doi: 10.1056/NEJMoa2601103
Cardiovascular disease is the number one age-related disease and the leading cause of age-related death in the world. What if you can treat it not just with positive lifestyle changes but also with a clinically-proven longevity supplement? Chris Mirabile, founder and CEO of NOVOS, is here once again to present the findings of their newly released clinical trials focused on cardiovascular health. Joining Zach Gurick, he unpacks the background and data behind their product NOVOS Core, which shows great success in reversing biological age and improving heart health. Discover what the latest science says about slowing aging, and how a simple supplement with actual clinical proof can make a real difference in your body.The information presented in Fully Alive is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition or treatment and before making changes to your health regimen. Guests' opinions are their own and do not necessarily reflect those of the podcast host, production team, or sponsors.Love the show? Subscribe, rate, review, & share! https://www.shellpoint.org/podcast/
Better Edge : A Northwestern Medicine podcast for physicians
In this episode of Better Edge, Palak Shah, MD, the new chief of the Section of Heart Failure and medical director of the Heart Transplant Program at Northwestern Medicine Bluhm Cardiovascular Institute, shares how his career has been shaped by the transformation of advanced heart failure care, from LVADs to transplantation. Dr. Shah discusses his clinical training and research, his systems-based vision for delivering advanced heart failure and surgical care closer to patients' communities, and his commitment to equitable access, innovation and multidisciplinary collaboration. The conversation offers referring physicians insight into how Bluhm Cardiovascular Institute is shaping the next era of personalized, longitudinal heart failure care across a regional health system.
In this episode, we review the high-yield topic of Obstructive Shock from the Cardiovascular section at Medbullets.comFollow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets
In this episode, we review the high-yield topic of Other Cyanotic Congenital Heart Defects from the Cardiovascular section at Medbullets.comFollow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets
In this episode, we review the high-yield topic of Hypercholersterolemia / Hyperlipidemia from the Cardiovascular section at Medbullets.comFollow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets
In this episode, we review the high-yield topic of Atrial Septal Defect (ASD) from the Cardiovascular section at Medbullets.comFollow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets
In this episode, we review the high-yield topic of Preoperative Evaluation from the Cardiovascular section at Medbullets.comFollow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets
In this episode, we review the high-yield topic of Superficial Thrombophlebitis from the Cardiovascular section at Medbullets.comFollow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets
In this episode, we review the high-yield topic of Distributive Shock from the Cardiovascular section at Medbullets.comFollow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets
If you enjoy this episode, we're sure you will enjoy more content like this on The Occult Rejects. In fact, we have curated playlists on occult topics like grimoires, esoteric concepts and phenomena, occult history, analyzing true crime and cults with an occult lens, Para politics, and occultism in music. Whether you enjoy consuming your content visually or via audio, we've got you covered - and it will always be provided free of charge. So, if you enjoy what we do and want to support our work of providing accessible, free content on various platforms, please consider making a donation to the links provided below. Thank you and enjoy the episode!Links For The Occult Rejectshttps://linktr.ee/theoccultrejectsOccult Research Institutehttps://www.occultresearchinstitute.org/Cash Apphttps://cash.app/$theoccultrejectsVenmo@TheOccultRejectsBuy Me A Coffeebuymeacoffee.com/TheOccultRejectsPatreonhttps://www.patreon.com/TheOccultRejectsPrimary / traditional texts and core religious sourcesĀnāpānasati Sutta (MN 118), translated by Thanissaro Bhikkhu, Access to Insight. Best primary source for Buddhist mindfulness of breathing.“Ḏekr / Dhikr,” Encyclopaedia Iranica. Strong source for Sufi remembrance, rhythmic repetition, posture, and breathing-linked practice.“Hesychasm,” Encyclopaedia Britannica. Good general source for the Christian contemplative tradition of stillness, uninterrupted prayer, and the Jesus Prayer.“Saint Gregory Palamas,” Encyclopaedia Britannica. Useful for the role of bodily posture and controlled breathing in Hesychast prayer.Crowley, Aleister. Liber E vel Exercitiorum. Primary text for Crowley's explicit inclusion of “Pranayama – Regularisation of the Breathing” in occult training.Crowley, Aleister. Book Four, Part 1. Useful for Crowley's statement that pranayama is useful in “quieting the emotions and appetites.”Historical / religious context“Prana,” Encyclopaedia Britannica. Best short source for the deep Indian background: prāṇa, the five prāṇas, and breath as vital force.“Pranayama,” Encyclopaedia Britannica. Best short source for classical Yoga: pranayama as the fourth limb aimed toward samādhi.“Hatha Yoga,” Encyclopaedia Britannica. Useful for the force-oriented turn: bodily mastery, purification, and regulation of breathing.“Qi,” Encyclopaedia Britannica. Good for Daoist and Chinese background: qi as psychophysical energy and breath-linked vital force.“Qigong,” Encyclopaedia Britannica. Useful for qigong as a discipline combining movement, breathing, and mental concentration.“Are Kabbalistic Meditations all about Ecstasy?” in Hermes Explains (Cambridge). Strong academic source for Abraham Abulafia and ecstatic Kabbalah.“Classical Kabbalah, Its History and Symbolic Universe.” Useful academic source noting ecstatic Kabbalah's breathing exercises, postures, and developed techniques.Neuroscience / physiology / altered statesAshhad, Kam, Del Negro, and Feldman. “Breathing Rhythm and Pattern and Their Influence on Emotion.” Annual Review of Neuroscience (2022). One of the best overview papers for the whole episode.Yackle et al. “Breathing control center neurons that promote arousal in mice.” Science (2017). Key source for the preBötzinger complex / calm-vs-arousal section.Schottelkotte and Dutschmann. “Forebrain control of breathing: Anatomy and potential functions.” Frontiers in Neurology (2022). Best source for cortex, amygdala, hippocampus, hypothalamus, and thalamus in breathing control.Krohn et al. “The integrated brain network that controls respiration.” eLife (2023). Strong review for respiration as part of a larger integrated brain network.Heck et al. “Breathing as a fundamental rhythm of brain function.” Human MEG work on respiration-modulated brain oscillations across frequency bands and brain regions.(Note: the specific MEG paper surfaced in earlier research as the respiration-modulated oscillations study; the review sources above are the strongest anchors for that section.)Zelano et al. “Nasal Respiration Entrains Human Limbic Oscillations and Modulates Cognitive Function.” Journal of Neuroscience (2016). One of the most important human papers in the whole script.Schreiner et al. “Respiration modulates sleep oscillations and memory reactivation in humans.” Nature Communications (2023). Best source for the sleep-spindle / memory-reactivation section.Zaccaro et al. “How Breath-Control Can Change Your Life: A Systematic Review on Psychophysiological Correlates of Slow Breathing.” Frontiers in Human Neuroscience / PMC version (2018). Best broad source for slow breathing under 10 breaths per minute.Shao, Man, and Lee. “The Effect of Slow-Paced Breathing on Cardiovascular and Emotion Functions: A Meta-Analysis and Systematic Review.” Mindfulness (2024). Useful for the stabilizing-road section.Kozhevnikov et al. “Neurocognitive and Somatic Components of Temperature Increases during g-Tummo Meditation.” PLoS ONE (2013). Best source for vase breathing and inner-heat claims.Zhang et al. “Hyperventilation in neurological patients: from physiology to outcome evidence.” Useful source for hypocapnia, cerebral vasoconstriction, and reduced cerebral blood flow.Havenith et al. “Decreased CO2 saturation during circular breathwork supports emergence of altered states of consciousness.” Communications Psychology (2025). The key modern paper for circular breathwork and altered-state onset. Also want to remind people about the website, if you're into reading we have tons of information by multiple contributors, and we got t-shirts up on the site if you're interested. Fun fact, the art is all based on the eyeball. Now let me introduce the rest of the panel and guests.
This week we review a recent work from the CT group at NY Presbyterian assessing the impact of phenylephrine during pediatric congenital CT scans to lower heart rate. Why is a lower heart rate better for CCT's? Should this agent be routinely employed for this indication during CT scans in children? Dr. Yosef Cohen, pediatrics resident at the Children's Hospital at Montefiore shares his insights from a recent work he co-authored. doi: 10.1093/ehjimp/qyag023. eCollection 2025 Aug.